120 related articles for article (PubMed ID: 2073911)
1. Lipoproteins and coronary heart disease in the Helsinki Heart Study.
Mänttäri M; Huttunen JK; Koskinen P; Manninen V; Tenkanen L; Heinonen OP; Frick MH
Eur Heart J; 1990 Dec; 11 Suppl H():26-31. PubMed ID: 2073911
[TBL] [Abstract][Full Text] [Related]
2. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Frick MH
Am J Cardiol; 1989 May; 63(16):42H-47H. PubMed ID: 2650524
[TBL] [Abstract][Full Text] [Related]
3. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
[TBL] [Abstract][Full Text] [Related]
4. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
[TBL] [Abstract][Full Text] [Related]
5. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
[TBL] [Abstract][Full Text] [Related]
6. Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Huttunen JK; Frick MH; Heinonen OP; Heinsalmi P; Manninen V; Mänttäri M; Romo M
Drugs; 1988; 36 Suppl 3():32-6. PubMed ID: 3076118
[TBL] [Abstract][Full Text] [Related]
7. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
[TBL] [Abstract][Full Text] [Related]
8. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
[TBL] [Abstract][Full Text] [Related]
10. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Koskinen P; Mänttäri M; Manninen V; Huttunen JK; Heinonen OP; Frick MH
Diabetes Care; 1992 Jul; 15(7):820-5. PubMed ID: 1516498
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
Knipscheer HC; Nurmohamed MT; Van den Ende A; Plaat B; Pruijs HJ; Mulder WJ; Kastelein JJ
J Intern Med; 1994 Oct; 236(4):377-84. PubMed ID: 7931040
[TBL] [Abstract][Full Text] [Related]
12. Effect of gemfibrozil on the concentration and composition of serum lipoproteins. A controlled study with special reference to initial triglyceride levels.
Mänttäri M; Koskinen P; Manninen V; Huttunen JK; Frick MH; Nikkilä EA
Atherosclerosis; 1990 Feb; 81(1):11-7. PubMed ID: 2407250
[TBL] [Abstract][Full Text] [Related]
13. The Helsinki Heart Study: central findings and clinical implications.
Huttunen JK; Manninen V; Mänttäri M; Koskinen P; Romo M; Tenkanen L; Heinonen OP; Frick MH
Ann Med; 1991 Apr; 23(2):155-9. PubMed ID: 2069792
[TBL] [Abstract][Full Text] [Related]
14. Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study.
Manninen V; Koskinen P; Manttari M; Huttunen JK; Canter D; Frick HM
Am J Cardiol; 1990 Sep; 66(6):24A-27A. PubMed ID: 2392990
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Hay JW; Sterling KL
Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
[TBL] [Abstract][Full Text] [Related]
16. HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.
Frick MH; Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Mänttäri M
Drugs; 1990; 40 Suppl 1():7-12. PubMed ID: 2289410
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
[TBL] [Abstract][Full Text] [Related]
18. High-density lipoprotein cholesterol elevation with gemfibrozil: effects of baseline level and modifying factors.
Mänttäri M; Tenkanen L; Mäenpää H; Manninen V; Huttunen JK
Clin Pharmacol Ther; 1993 Oct; 54(4):437-47. PubMed ID: 8222487
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
Athyros VG; Papageorgiou AA; Avramidis MJ; Kontopoulos AG
Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
